ChemicalBook > CAS DataBase List > Iron-dextran

Iron-dextran

CAS No.9004-66-4
Chemical Name:Iron-dextran
CBNumber:CB9139534
Molecular Formula:FeH2O4S
Formula Weight:153.92348
MOL File:9004-66-4.mol

Iron-dextran Property

storage temp. Room Temperature
solubility Water (Slightly)
form solution
color Very Dark Red to Black
PH 4 - 6.5
biological source synthetic
Water Solubility Iron, ~100?mg/mL in water
EWG's Food Scores 1
FDA UNII 95HR524N2M
NCI Drug Dictionary iron dextran complex
Proposition 65 List Iron Dextran Complex
IARC 2B (Vol. 2, Sup 7) 1987
EPA Substance Registry System Iron dextran (9004-66-4)
UNSPSC Code 12352201
NACRES NA.25

Safety

Hazard Codes :Xn,T
Risk Statements :40-42/43-43-45
Safety Statements :23-26-36/37/39-45-36-36/37-53
WGK Germany :-
RTECS :NI2200000
Hazardous Substances Data :9004-66-4(Hazardous Substances Data)
Toxicity :LD50 i.v. in mice: 2240 mg Fe/kg (Beliles)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal wordDanger
Hazard statements H317-H350
Precautionary statements P202-P261-P272-P280-P302+P352-P308+P313

Iron-dextran Price More Price(2)

Brand: Sigma-Aldrich(India)
Product number: D8517
Product name : Iron–Dextran
Purity: solution
Packaging: 25ML
Price: ₹13682.8
Updated: 2022/06/14
Buy: Buy

Brand: Sigma-Aldrich(India)
Product number: D8517
Product name : Iron–Dextran
Purity: solution
Packaging: 100ML
Price: ₹30537.33
Updated: 2022/06/14
Buy: Buy

Iron-dextran Chemical Properties,Usage,Production

Description Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292)
Iron-Dextran is for the parenteral treatment of iron-deficiency anemia in humans and baby pigs. Can be used as a reagent.
Chemical Properties Light to dark brown powder. Colloidal suspension of an iron-dextran complex in water. pH 5.2-6.5.
History The therapeutic value of colloidal iron preparations was first reported in the 1950's by London and Twigg. Numerous attempts have been made to improve these iron preparations Thus dextran ([h] 0.05) is first heated with alkali, and is then neutralized in the presence of ferric chloride solution. Studies on this product have revealed that each particle consists of a central iron core, approximately 3nm diameter, surrounded by a dextran sheath of approximately 13nm diameter. The complex is visualized as a particle formed by a protective sheath of dextran attached by terminal metasaccharinic acid units to a b-FeOOH core. A solution of this complex containing 5% iron and 20% dextran (Imferon ™ ) is suitable for intramuscular and intravenous injection for treating iron deficiency anemia. The product is currently used widely for treating anemia in new-born piglets.
The use of these preparations has been re-examined in humans and a dramatic rise in hemoglobin was reported following intravenous infusion. The solution is best administered together with glucose solutions.
Uses Hematinic.
Uses Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.
brand name Dexferrum (Luitpold); Infed (Wat son); Proferdex (New River).
Reactivity Profile Iron-dextran is unstable at a pH of 5 and decomposes at 149-158° F. Iron-dextran may be sensitive to prolonged exposure to air.
Health Hazard SYMPTOMS: The symptoms associated with exposure to Iron-dextran are headaches, vomiting, and dizziness.
Fire Hazard Iron-dextran is combustible.
Clinical Use Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)

Treatment of iron deficiency during ESA therapy especially if serum ferritin is very low (<50 nanograms/mL)
Drug interactions Potentially hazardous interactions with other drugs
Dimercaprol: avoid concomitant use.
Oral iron: reduced absorption of oral iron
Carcinogenicity Iron dextran complex is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.
Metabolism After intravenous infusion, iron dextran is taken up by the cells of the reticuloendothelial cells, particularly in the liver and spleen. The reticuloendothelial cells gradually separate iron from the iron-dextran complex. Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin.
Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.